Cannabinoid products for pain management: recommendations from the São Paulo State Society of Anesthesiology.

There is growing interest in using cannabinoids across various clinical scenarios, including pain medicine, leading to the disregard of regulatory protocols in some countries. Legislation has been implemented in Brazil, specifically in the state of São Paulo, permitting the distribution of cannabinoid products by health authorities for clinical purposes, free of charge for patients, upon professional prescription. Thus, it is imperative to assess the existing evidence regarding the efficacy and safety of these products in pain management. In light of this, the São Paulo State Society of Anesthesiology (SAESP) established a task force to conduct a narrative review on the topic using the Delphi method, requiring a minimum agreement of 60% among panelists. The study concluded that cannabinoid products could potentially serve as adjuncts in pain management but stressed the importance of judicious prescription. Nevertheless, this review advises against their use for acute pain and cancer-related pain. In other clinical scenarios, established treatments should take precedence, particularly when clinical protocols are available, such as in neuropathic pain. Only patients exhibiting poor therapeutic responses to established protocols or demonstrating intolerance to recommended management may be considered as potential candidates for cannabinoids, which should be prescribed by physicians experienced in handling these substances. Special attention should be given to individual patient characteristics and the likelihood of drug interactions.

Transdermal Opioids and the Quality of Life of the Cancer Patient: A Systematic Literature Review.

OBJECTIVE: This systematic literature review aims to evaluate the effectiveness of transdermal opioids in managing cancer pain and their impact on the quality of life (QoL) of patients. DATA SOURCES: A systematic literature review conducted following the PRISMA protocol, focusing on randomized clinical trials found in the Lilacs, Embase, PubMed, and SciELO databases over the last 20 years. STUDY SELECTION AND DATA EXTRACTION: We included randomized clinical trials, published in English, Portuguese, or Spanish, which assessed the impact of transdermal opioids on the QoL. Data extraction was facilitated using the Rayyan app. DATA SYNTHESIS: Six articles meeting the inclusion and exclusion criteria were analyzed. These studies covered a population ranging from 24 to 422 cancer patients experiencing moderate to severe pain. The risk of bias was assessed in each study, generally being categorized as uncertain or high. RELEVANCE TO PATIENT CARE AND CLINICAL PRACTICE: The findings indicate that the analgesic effectiveness and side effects of transdermal formulations (specifically buprenorphine and fentanyl) for managing moderate to severe cancer pain are comparable to, or in some cases superior to, those of oral opioids traditionally employed. CONCLUSIONS: Transdermal therapy was suggested to have several advantages over oral opioid therapy in enhancing cancer patients' QoL. These benefits span various dimensions, including pain management, physical functioning, mental health, vitality, overall patient improvement, anger/aversion, strength/activity, general QoL, cognitive and emotional functions, fatigue, and insomnia.

Assessment of sleep and stress level in individuals with chronic pain.

Introduction: The experience of living with chronic pain allows for the appearance of changes in sleep patterns, mood, and stress levels. Objective: To describe the phases of stress and the quality of sleep in patients with chronic pain. Material and Methods: Cross-sectional study carried out at the pain clinic of the HUPES Complex, Salvador-Bahia. Data collection between March 2016 and November 2017. Instruments: Sociodemographic questionnaire, Numerical Pain Scale (EVN), Mini-Sleep Questionnaire (MSQ), and Stress Symptoms Inventory for LIPP adults (ISSL). Categorical variables were expressed by absolute and relative frequency and quantitative variables by means and standard deviation (SD). The comparison of categorical variables was performed using the chi-square test. Values of p<0.05 were considered statistically significant. Results: Mean age (standard deviation) of 50.0 (10) years, 89.6% of whom were female. Predominance of people with a partner, with religion, high school, and unemployed or removed by the INSS. They have severe sleep disorders, severe pain, and the presence of stress in the resistance phase. Most subjects reveal that they have improved with the treatment and have moderate self-esteem and personal satisfaction, despite the presence of anxious and depressive symptoms. Conclusion: Chronic pain has a very significant impact on life, increasing the level of stress, compromising and limiting daily activities, and showing more presence of anxious and depressive symptoms in people who suffer from chronic pain.

Clinical evaluation and prevalence of fibromyalgia in hepatitis C patients / Avaliação clínica e prevalência de fibromialgia em pacientes portadores de hepatite C

ABSTRACT BACKGROUND AND OBJECTIVES: The worldwide distribution and etiology of fibromyalgia are poorly understood. It is believed that different factors are involved, such as hepatitis C virus infection. The aim of this study was to estimate the prevalence of fibromyalgia in hepatitis C virus infected patients, trying to identify the occurrence of liver injury, extrahepatic clinical manifestations, anxiety, depression, and the impact on the quality of life. METHODS: This is a cross-sectional study of patients (n=118) with hepatitis C virus infection who were compared with a group of clinically stable patients not infected with the hepatitis C virus (n=118). The Anxiety and Depression Questionnaire was applied, and for those diagnosed with fibromyalgia, the Fibromyalgia Impact Questionnaire. Liver biopsies were analyzed according to the METAVIR classification. The Schirmer test was performed to investigate abnormal tear production in the studied patients. Data analysis was performed using the Statistical Package for Social Sciences (SPSS) software, v.10.0. RESULTS: The prevalence of fibromyalgia in infected patients was 7.6%. In patients infected with fibromyalgia, a significant prevalence of anxiety and depression was observed. Fibromyalgia Impact Questionnaire scores were higher in infected patients with fibromyalgia. When comparing the complementary tests in infected patients with and without fibromyalgia, no significant differences were found for the Schirmer test, viral genotype, and degree of fibrosis and liver inflammation. CONCLUSION: In females, there was a positive relationship between hepatitis C virus infection, fibromyalgia, and extrahepatic symptoms, which translates into a higher prevalence of anxiety and depression and impaired quality of life.

RESUMO JUSTIFICATIVA E OBJETIVOS: A fibromialgia tem distribuição mundial e etiologia pouco comprendida. Acredita-se no envolvimento de diferentes fatores, como a infecção pelo vírus da hepatite C. O objetivo deste estudo foi estimar a prevalência de fibromialgia em pacientes infectados pelo vírus da hepatite C, procurando identificar a ocorrência de lesão hepática, manifestações clínicas extra-hepáticas, ansiedade, depressão e o impacto na qualidade de vida. MÉTODOS: Trata-se de um estudo de corte transversal com pacientes (n=118) portadores de infecção pelo vírus da hepatite C que foram comparados a um grupo composto de pacientes clinicamente estáveis e não infectados pelo vírus da hepatite C (n=118). Foi aplicado o Questionário de Ansiedade e Depressão, e para os que obtivessem o diagnóstico de fibromialgia, o Questionário de Impacto da Fibromialgia. As biopsias hepáticas foram analisadas de acordo com a classificação METAVIR. Foi realizado o teste de Schirmer para a pesquisa de lacrimejamento anormal nos pacientes estudados. A análise dos dados foi realizada através do programa Statistical Package for Social Sciences (SPSS) v.10.0. RESULTADOS: A prevalência de fibromialgia em pacientes infectados foi de 7,6%. Nos pacientes infectados com fibromialgia observou-se prevalência significativa de ansiedade e depressão. A pontuação do Questionário de Impacto da Fibromialgia foi maior nos pacientes infectados e com fibromialgia. Quando se relacionou os exames complementares em infectados com e sem fibromialgia, não foram constatadas diferenças significativas para o teste de Schirmer, genótipo viral e grau de fibrose e inflamação hepática. CONCLUSÃO: Nos indivíduos do sexo feminino, observou-se uma relação positiva entre a infecção pelo vírus da hepatite C, fibromialgia e sintomas extra-hepáticos, que se traduz em maior prevalência de ansiedade e depressão e em comprometimento na qualidade de vida.

Efficacy and safety of loxoprofen sodium topical patch for the treatment of pain in patients with minor acute traumatic limb injuries in Brazil: a randomized, double-blind, noninferiority trial.

Posttraumatic injury pain is commonly treated with oral nonsteroidal anti-inflammatory drugs. However, oral nonsteroidal anti-inflammatory drugs cause several adverse events, with topical formulations arising as an important alternative. Therefore, we aimed at evaluating the efficacy and safety of loxoprofen patch (LX-P) in the treatment of patients with posttraumatic pain. This phase III, randomized, double-blind, noninferiority study enrolled Brazilian patients aged 18 to 65 years diagnosed with lower and upper limb posttraumatic injury who were experiencing moderate or severe pain. Patients were assigned to active LX-P or to loxoprofen tablet (LX-T), and pain intensity was measured based on a visual analog scale score variation after 7 days of treatment. Data on clinical symptoms, rescue medication use, and adverse events were also collected. Visual analog scale score variation was compared using a 10% noninferiority margin. Two hundred forty-two patients were randomly assigned to LX-P (n = 123) or to LX-T (n = 119). The results showed a reduction in pain after 7 days of treatment: -49.96 (n = 118; SE 1.7) in the LX-P and -47.71 (n = 117; SE 1.6) in the LX-T groups (difference of -2.25; 95% CI: -5.97 to 1.47; P = 0.23). On the safety analysis, the LX-T group presented twice as many patients with treatment-emergent adverse events as the LX-P group (30.8% and 14.2%, respectively). A sensitivity analysis demonstrated that rescue medication use has not affected the primary end point. This study showed that LX-P has a comparable efficacy to LX-T, but with a better safety profile, being a therapeutic option for the treatment of posttraumatic injury pain.

Latin American and Caribbean consensus on noninvasive central nervous system neuromodulation for chronic pain management (LAC2-NIN-CP).

INTRODUCTION: Chronic pain (CP) is highly prevalent and generally undertreated health condition. Noninvasive brain stimulation may contribute to decrease pain intensity and influence other aspects related to CP. OBJECTIVE: To provide consensus-based recommendations for the use of noninvasive brain stimulation in clinical practice. METHODS: Systematic review of the literature searching for randomized clinical trials followed by consensus panel. Recommendations also involved a cost-estimation study. RESULTS: The systematic review wielded 24 transcranial direct current stimulation (tDCS) and 22 repetitive transcranial magnetic stimulation (rTMS) studies. The following recommendations were provided: (1) Level A for anodal tDCS over the primary motor cortex (M1) in fibromyalgia, and level B for peripheral neuropathic pain, abdominal pain, and migraine; bifrontal (F3/F4) tDCS and M1 high-definition (HD)-tDCS for fibromyalgia; Oz/Cz tDCS for migraine and for secondary benefits such as improvement in quality of life, decrease in anxiety, and increase in pressure pain threshold; (2) level A recommendation for high-frequency (HF) rTMS over M1 for fibromyalgia and neuropathic pain, and level B for myofascial or musculoskeletal pain, complex regional pain syndrome, and migraine; (3) level A recommendation against the use of anodal M1 tDCS for low back pain; and (4) level B recommendation against the use of HF rTMS over the left dorsolateral prefrontal cortex in the control of pain. CONCLUSION: Transcranial DCS and rTMS are recommended techniques to be used in the control of CP conditions, with low to moderate analgesic effects, and no severe adverse events. These recommendations are based on a systematic review of the literature and a consensus made by experts in the field. Readers should use it as part of the resources available to decision-making.

Optimizing cancer pain management in resource-limited settings.

PURPOSE: Adequate cancer pain management (CPM) is challenging in resource-limited settings, where current international guideline recommendations are difficult to implement owing to constraints such as inadequate availability and accessibility of opioids, limited awareness of appropriate opioid use among patients and clinicians, and lack of guidance on how to translate the best evidence into clinical practice. The multinational and multidisciplinary CAncer Pain managEment in Resource-limited settings (CAPER) Working Group proposes a two-step initiative to bridge clinical practice gaps in CPM in resource-limited settings. METHODS: A thorough review of the literature, a steering committee meeting in February 2017, and post-meeting teleconference discussions contributed to the development of this initiative. As a first step, we developed practical evidence-based CPM algorithms to support healthcare providers (HCPs) in tailoring treatment according to availability of and access to resources. The second part of the initiative proposes a framework to support an effective implementation of the CPM algorithms that includes an educational program, a pilot implementation, and an advocacy plan. RESULTS: We developed CPM algorithms for first-line use, breakthrough cancer pain, opioid rotation, and refractory cancer pain based on the National Comprehensive Cancer Network guidelines and expert consensus. Our proposed educational program emphasizes the practical elements and illustrates how HCPs can provide optimal CPM according to evidence-based guidelines despite varied resource limitations. Pilot studies are proposed to demonstrate the effectiveness of the algorithms and the educational program, as well as for providing evidence to support a draft advocacy document, to lobby policymakers to improve availability and accessibility of analgesics in resource-limited settings. CONCLUSIONS: These practical evidence-informed algorithms and the implementation framework represent the first multinational step towards achieving optimal CPM in resource-limited settings.

Persistent idiopathic facial pain, a diagnosis and treatment of challenge. Case report

ABSTRACT BACKGROUND AND OBJECTIVES: Persistent idiopathic facial pain is a chronic disease with neuropathic origin, whose etiology is usually unknown; it is a medical condition that does not respond satisfactorily to drug therapy. It is also a disease with a major impact on patient quality of life and difficult to diagnose. This study aimed to report the diagnosis of a complex, persistent idiopathic facial pain, the pharmacological intervention taken and the adoption of integrative and complementary practices for the management of persistent idiopathic facial, as well as the clinical course and the impact of these actions on the patient's quality of life. CASE REPORT: A female patient, 52, diagnosed 06 years ago as a carrier of persistente idiopathic facial pain associated with bruxism and temporomandibular disorders. The patient presented with a complaint of orofacial pain which did not meet the diagnostic criteria for temporomandibular disorders. The patient also presented myofascial and trigeminal neuralgia pain in the left buccal region which emerged after performing a root canal procedure. The therapeutic plan adopted was based on pharmacological therapy with pregabalin (450mg) in combination with venlafaxine hydrochloride (150mg), continuously. As additional measures, weekly acupuncture sessions, therapy sessions with psychologists, including hypnosis and meditation, as well as peripheral nerve and a venous block during crises and botulinum toxin application were applied. CONCLUSION: The therapeutic plan adopted led to a considerable improvement in the patient's quality of life, evidenced by the reduction in pain intensity and a decrease in the frequency of painful crises. The need for interdisciplinary monitoring, as it is a multifactorial disease, as well as for the ongoing training of various categories of health professionals involved in the treatment of persistent idiopathic facial, given that it is a complication which is rare and difficult to diagnose, is observed.

RESUMO Justificativa e objetivos: A dor facial idiopática persistente é uma doença crônica de origem neuropática cuja etiologia é normalmente desconhecida. É uma condição médica que não responde satisfatoriamente à farmacoterapia. Também é uma doença com grande impacto na qualidade de vida do paciente, e difícil de diagnosticar. O objetivo deste estudo foi reportar o diagnóstico de dor facial idiopática persistente, complexa, a intervenção farmacológica usada e a adoção de práticas integrativas e complementares para o manuseio da dor facial idiopática persistente, além do curso clínico e o impacto dessas ações na qualidade de vida do paciente. RELATO DO CASO: Paciente do sexo feminino, 52 anos, diagnosticada há 6 anos como portadora de dor facial idiopática persistente associada a bruxismo e distúrbio temporomandibular. A paciente apresentou-se com queixa de dor orofacial que não atendeu os critérios diagnósticos de distúrbio temporomandibular. A paciente também apresentou dor miofascial e neuralgia do trigêmeo na região esquerda da boca que surgiram depois de um procedimento de tratamento de canal. O plano terapêutico adotado foi pregabalina (450mg) em combinação com cloridrato de venlafaxina (150mg), contínuo. Como medidas adicionais, sessões semanais de acupuntura, terapia com psicólogo, incluindo hipnose e meditação, além de bloqueio do nervo periférico e bloqueio venoso durante as crises e aplicação de toxina botulínica. CONCLUSÃO: O plano terapêutico adotado trouxe melhora considerável na qualidade de vida da paciente, evidenciada pela redução da intensidade da dor e pela diminuição na frequência das crises dolorosas. Há necessidade de monitoramento interdisciplinar, por ser uma doença multifatorial, e de capacitação constante nas diversas categorias de profissionais de saúde envolvidos no tratamento da dor facial idiopática persistente, vista ser uma complicação rara e difícil de diagnosticar.

Undertreatment of pain and low use of opioids in Latin America.

Pain is highly prevalent among the adult Latin American population. However, many patients with moderate to severe pain do not have access to effective pain management with opioids due to limited access to healthcare, overuse of nonopioid analgesics, regulatory barriers and lack of appropriate information about opioids. There is scarce training on use of opioids among physicians and other healthcare providers, which leads to misconceptions, mainly related to a fear of prescribing opioids. Although opioids are safe and effective drugs for the treatment of moderate to severe chronic pain, the use of opioids in Latin American nations is clearly below standards compared with developed countries.